Skinvisible (SKVI) Total Debt Growth (1y) (2012 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Total Debt Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.22 Bn | 626.46 Bn | 17.26 Bn | -2.50% |
| 2 | AbbVie | 440.28 Bn | 433.71 Bn | 12.70 Bn | -4.39% |
| 3 | Merck | 364.30 Bn | 357.16 Bn | 12.21 Bn | 52.27% |
| 4 | Novartis Ag | 268.44 Bn | 260.75 Bn | 11.24 Bn | 15.32% |
| 5 | Pfizer | 158.60 Bn | 146.90 Bn | 10.94 Bn | 2.26% |
| 6 | Sanofi | 52.56 Bn | 45.18 Bn | 10.79 Bn | 8.51% |
| 7 | Revolution Medicines | 44.31 Bn | 44.31 Bn | - | - |
| 8 | Incyte | 24.98 Bn | 20.45 Bn | 1.57 Bn | -17.14% |
| 9 | United Therapeutics | 21.16 Bn | 18.49 Bn | 683.80 Mn | - |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | -4.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.13% |
| Mar 31, 2026 | -5.23% |
| Dec 31, 2025 | 7.13% |
| Sep 30, 2025 | -0.43% |
| Jun 30, 2025 | -0.48% |
| Mar 31, 2025 | -0.31% |
| Dec 31, 2024 | -0.60% |
| Sep 30, 2024 | 6.82% |
| Jun 30, 2024 | 6.52% |
| Mar 31, 2024 | 6.27% |
| Dec 31, 2023 | -9.46% |
| Sep 30, 2023 | 65.41% |
| Jun 30, 2023 | 73.43% |
| Mar 31, 2023 | 82.34% |
| Dec 31, 2022 | 112.52% |
| Sep 30, 2022 | 22.35% |
| Jun 30, 2022 | 21.03% |
| Mar 31, 2022 | 19.10% |
| Dec 31, 2021 | 19.98% |
| Sep 30, 2021 | 281.88% |